{"nctId":"NCT02160808","briefTitle":"Secretin Infusion to Prevent Pancreatic Leaks Following Pancreatic Resection","startDateStruct":{"date":"2014-05","type":"ACTUAL"},"conditions":["Injury of Body of Pancreas"],"count":170,"armGroups":[{"label":"Secretin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Secretin"]},{"label":"Saline","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Secretin","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Scheduled for pancreatic surgery requiring pancreatic resection at DHMC\n2. Age greater than 18 years old\n3. Ability to provide written informed consent\n\nExclusion Criteria:\n\n1. Inability to provide written informed consent\n2. Current ongoing acute pancreatitis\n3. Pregnant or nursing mothers\n4. Any medical condition which in the judgment of the Investigator renders participation in this study medically inadvisable.\n5. Participation in an investigational clinical study for a drug or medical device within 30 days prior to Visit 1.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"100 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Biochemical Leak/Grade B Fistula/Grade C Fistula","description":"Outcome based on revised ISGPS Guidelines which require a three day drain amylase concentration greater than 3x the normal serum amylase concentration. Biochemical leaks are the mildest for of fistula which have no clinical consequence. Grade B fistula are more severe requiring usually percutaneous drainage placement. Grade C fistula are most severe resulting in significant morbidity and/or death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Intra-operative Intervention, Subsequent Biochemical Leak or B/C Fistula After Drug Administration","description":"Following the administration of Secretin or Placebo intraoperatively, the surgeon will have the opportunity to evaluate the anastomosis to determine if there is ongoing leak. If there is ongoing leak, then the surgeon will be able to treat the leak intra-operatively prior to operative closure. In those patients in whom an intervention was performed, they were subsequently evaluated to determine if they developed a biochemical leak or grade B/C fistula.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Length of Hospitalization","description":"Surrogate marker for operative success","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","spread":"6.5"},{"groupId":"OG001","value":"10.2","spread":"5.5"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":15,"n":87},"commonTop":["Hypotension","Superficial Surgical Site Infection","Hypertension","Hemorrhage","Chyle Leak"]}}}